TY  - JOUR
AU  - Velicković, Milena
AU  - Pejnović, Nada
AU  - Petrović, Renata
AU  - Mitrović, Slobodanka
AU  - Jeftić, Ilija
AU  - Kanjevac, Tatjana
AU  - Lukić, Aleksandra
PY  - 2016
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2135
AB  - BACKGROUND: Interleukin-33 (IL-33) is a recently identified cytokine belonging to the IL-1 family and ligand for the IL-1 receptor-related protein ST2. IL-33/ST2 signaling plays a critical role in allergy, autoimmunity, and chronic inflammatory disorders, but its role in the pathogenesis of periapical lesions is unknown. We aimed to investigate the expression patterns of IL-33 and ST2 in human periapical lesions. METHODS: Periapical lesions (n = 36) and healthy periapical tissues (n = 10) were evaluated by immunohistochemistry using antibodies specific for human IL-33 and ST2. Lesion samples were further analyzed by double immunofluorescence to assess IL-33/ST2 co-expression. RESULTS: The numbers of IL-33- and ST2-positive fibroblasts were significantly higher in periapical lesions compared to healthy periapical tissues (both P  lt  0.05), while the numbers of IL-33-and ST2-positive endothelial cells were similar (both P > 0.05). There were no significant differences in the numbers of IL-33-and ST2-positive fibroblasts and endothelial cells between periapical granulomas and radicular cysts (all P > 0.05). Similarly, numbers of ST2-positive mononuclear cells did not differ between periapical granulomas and radicular cysts (P > 0.05). The majority of epithelial cells in radicular cysts were IL-33 positive, while the small proportion of epithelial cells was ST2 positive. Double immunofluorescence analysis revealed IL-33/ST2 co-expression in fibroblasts and endothelial cells. CONCLUSIONS: IL-33 and ST2 are expressed in periapical granulomas and radicular cysts. Increased numbers of IL-33-and ST2-positive fibroblasts in periapical lesions when compared to healthy periapical tissues suggest that IL-33/ST2 signaling may be involved in periapical inflammation and tissue fibrosis.
PB  - Wiley, Hoboken
T2  - Journal of Oral Pathology & Medicine
T1  - Expression of interleukin-33 and its receptor ST2 in periapical granulomas and radicular cysts
VL  - 45
IS  - 1
SP  - 70
EP  - 76
DO  - 10.1111/jop.12312
ER  - 

@article{
author = "Velicković, Milena and Pejnović, Nada and Petrović, Renata and Mitrović, Slobodanka and Jeftić, Ilija and Kanjevac, Tatjana and Lukić, Aleksandra",
year = "2016",
abstract = "BACKGROUND: Interleukin-33 (IL-33) is a recently identified cytokine belonging to the IL-1 family and ligand for the IL-1 receptor-related protein ST2. IL-33/ST2 signaling plays a critical role in allergy, autoimmunity, and chronic inflammatory disorders, but its role in the pathogenesis of periapical lesions is unknown. We aimed to investigate the expression patterns of IL-33 and ST2 in human periapical lesions. METHODS: Periapical lesions (n = 36) and healthy periapical tissues (n = 10) were evaluated by immunohistochemistry using antibodies specific for human IL-33 and ST2. Lesion samples were further analyzed by double immunofluorescence to assess IL-33/ST2 co-expression. RESULTS: The numbers of IL-33- and ST2-positive fibroblasts were significantly higher in periapical lesions compared to healthy periapical tissues (both P  lt  0.05), while the numbers of IL-33-and ST2-positive endothelial cells were similar (both P > 0.05). There were no significant differences in the numbers of IL-33-and ST2-positive fibroblasts and endothelial cells between periapical granulomas and radicular cysts (all P > 0.05). Similarly, numbers of ST2-positive mononuclear cells did not differ between periapical granulomas and radicular cysts (P > 0.05). The majority of epithelial cells in radicular cysts were IL-33 positive, while the small proportion of epithelial cells was ST2 positive. Double immunofluorescence analysis revealed IL-33/ST2 co-expression in fibroblasts and endothelial cells. CONCLUSIONS: IL-33 and ST2 are expressed in periapical granulomas and radicular cysts. Increased numbers of IL-33-and ST2-positive fibroblasts in periapical lesions when compared to healthy periapical tissues suggest that IL-33/ST2 signaling may be involved in periapical inflammation and tissue fibrosis.",
publisher = "Wiley, Hoboken",
journal = "Journal of Oral Pathology & Medicine",
title = "Expression of interleukin-33 and its receptor ST2 in periapical granulomas and radicular cysts",
volume = "45",
number = "1",
pages = "70-76",
doi = "10.1111/jop.12312"
}

Velicković, M., Pejnović, N., Petrović, R., Mitrović, S., Jeftić, I., Kanjevac, T.,& Lukić, A.. (2016). Expression of interleukin-33 and its receptor ST2 in periapical granulomas and radicular cysts. in Journal of Oral Pathology & Medicine
Wiley, Hoboken., 45(1), 70-76.
https://doi.org/10.1111/jop.12312

Velicković M, Pejnović N, Petrović R, Mitrović S, Jeftić I, Kanjevac T, Lukić A. Expression of interleukin-33 and its receptor ST2 in periapical granulomas and radicular cysts. in Journal of Oral Pathology & Medicine. 2016;45(1):70-76.
doi:10.1111/jop.12312 .

Velicković, Milena, Pejnović, Nada, Petrović, Renata, Mitrović, Slobodanka, Jeftić, Ilija, Kanjevac, Tatjana, Lukić, Aleksandra, "Expression of interleukin-33 and its receptor ST2 in periapical granulomas and radicular cysts" in Journal of Oral Pathology & Medicine, 45, no. 1 (2016):70-76,
https://doi.org/10.1111/jop.12312 . .

TY  - JOUR
AU  - Milić, Vera
AU  - Jekić, Biljana
AU  - Luković, Ljiljana
AU  - Bunjevački, Vera
AU  - Milašin, Jelena
AU  - Novaković, I.
AU  - Damnjanović, Tatjana
AU  - Popović, Branka
AU  - Maksimović, Nela
AU  - Damjanov, Nemanja
AU  - Radunović, Goran
AU  - Pejnović, Nada
AU  - Krajinović, Maja
PY  - 2012
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/1741
AB  - Objectives Identifying genetic predictors of methotrexate (MTX) treatment response in patients with rheumatoid arthritis (RA) may have great importance for optimising drug doses required for clinical benefit without toxicity. In a group of 125 RA patients treated with MTX we investigated whether selected polymorphisms in genes relevant for MTX action (aminoimidazole-4-carboxiamide ribonucleotide transformylase, ATIC, and dihydrofolate reductase, DHFR) modulate disease activity and/or have impact on therapy side effects. Methods The efficacy of treatment was estimated both by the disease activity score in 28 joints (DAS28), based on EULAR criteria, and relative DAS28 (rDAS28) score. Adverse drug events (ADEs) were also recorded. RA patients were genotyped using the PCR-RFLP method, followed by an association study between ATIC -129T>G, DHFR -216T>C and DHFR -317A>G polymorphisms and the efficacy and toxicity of MTX. Results According to the EULAR response criteria, 96 RA patients (76.8%) were classified as responders (good/moderate response) and 29 (23.2%) as non-responders (poor response). rDAS28 values ranged from -0.01 to 0.80 (mean value 0.31 +/- 0.19). Among 125 patients enrolled in this study 39 experienced at least one side effect. The DHFR -317AA genotype was associated with the less favourable response (reduction in rDAS28 score, p=0.05). None of the analysed polymorphisms was associated with MTX toxicity. Conclusion RA patients with DHFR-317AA genotype had less favourable response to MTX Further studies in larger patient populations are necessary to confirm the relationship between the analysed polymorphisms and MTX treatment response.
PB  - Clinical & Exper Rheumatology, Pisa
T2  - Clinical & Experimental Rheumatology
T1  - Association of dihydrofolate reductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis
VL  - 30
IS  - 2
SP  - 178
EP  - 183
UR  - https://hdl.handle.net/21.15107/rcub_smile_1741
ER  - 

@article{
author = "Milić, Vera and Jekić, Biljana and Luković, Ljiljana and Bunjevački, Vera and Milašin, Jelena and Novaković, I. and Damnjanović, Tatjana and Popović, Branka and Maksimović, Nela and Damjanov, Nemanja and Radunović, Goran and Pejnović, Nada and Krajinović, Maja",
year = "2012",
abstract = "Objectives Identifying genetic predictors of methotrexate (MTX) treatment response in patients with rheumatoid arthritis (RA) may have great importance for optimising drug doses required for clinical benefit without toxicity. In a group of 125 RA patients treated with MTX we investigated whether selected polymorphisms in genes relevant for MTX action (aminoimidazole-4-carboxiamide ribonucleotide transformylase, ATIC, and dihydrofolate reductase, DHFR) modulate disease activity and/or have impact on therapy side effects. Methods The efficacy of treatment was estimated both by the disease activity score in 28 joints (DAS28), based on EULAR criteria, and relative DAS28 (rDAS28) score. Adverse drug events (ADEs) were also recorded. RA patients were genotyped using the PCR-RFLP method, followed by an association study between ATIC -129T>G, DHFR -216T>C and DHFR -317A>G polymorphisms and the efficacy and toxicity of MTX. Results According to the EULAR response criteria, 96 RA patients (76.8%) were classified as responders (good/moderate response) and 29 (23.2%) as non-responders (poor response). rDAS28 values ranged from -0.01 to 0.80 (mean value 0.31 +/- 0.19). Among 125 patients enrolled in this study 39 experienced at least one side effect. The DHFR -317AA genotype was associated with the less favourable response (reduction in rDAS28 score, p=0.05). None of the analysed polymorphisms was associated with MTX toxicity. Conclusion RA patients with DHFR-317AA genotype had less favourable response to MTX Further studies in larger patient populations are necessary to confirm the relationship between the analysed polymorphisms and MTX treatment response.",
publisher = "Clinical & Exper Rheumatology, Pisa",
journal = "Clinical & Experimental Rheumatology",
title = "Association of dihydrofolate reductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis",
volume = "30",
number = "2",
pages = "178-183",
url = "https://hdl.handle.net/21.15107/rcub_smile_1741"
}

Milić, V., Jekić, B., Luković, L., Bunjevački, V., Milašin, J., Novaković, I., Damnjanović, T., Popović, B., Maksimović, N., Damjanov, N., Radunović, G., Pejnović, N.,& Krajinović, M.. (2012). Association of dihydrofolate reductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. in Clinical & Experimental Rheumatology
Clinical & Exper Rheumatology, Pisa., 30(2), 178-183.
https://hdl.handle.net/21.15107/rcub_smile_1741

Milić V, Jekić B, Luković L, Bunjevački V, Milašin J, Novaković I, Damnjanović T, Popović B, Maksimović N, Damjanov N, Radunović G, Pejnović N, Krajinović M. Association of dihydrofolate reductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. in Clinical & Experimental Rheumatology. 2012;30(2):178-183.
https://hdl.handle.net/21.15107/rcub_smile_1741 .

Milić, Vera, Jekić, Biljana, Luković, Ljiljana, Bunjevački, Vera, Milašin, Jelena, Novaković, I., Damnjanović, Tatjana, Popović, Branka, Maksimović, Nela, Damjanov, Nemanja, Radunović, Goran, Pejnović, Nada, Krajinović, Maja, "Association of dihydrofolate reductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis" in Clinical & Experimental Rheumatology, 30, no. 2 (2012):178-183,
https://hdl.handle.net/21.15107/rcub_smile_1741 .